TrialJournal of thrombosis and haemostasis : JTH2022

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

Bettina Nowotny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.